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Abstract
Background:  One of the major challenges in currently chemotherapeutic theme is lacking
effective biomarkers for drug response and sensitivity. Our current study focus on two promising
biomarkers, ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer
susceptibility gene 1). To investigate their potential role in serving as biomarkers for drug sensitivity
in cancer patients with metastases, we statistically measure the mRNA expression level of ERCC1
and BRCA1 in tumor cells isolated from malignant effusions and correlate them with cisplatin and/
or docetaxel chemosensitivity.
Methods: Real-time quantitative PCR is used to analysis related genes expression in forty-six
malignant effusions prospectively collected from non-small cell lung cancer (NSCLC), gastric and
gynecology cancer patients. Viable tumor cells obtained from malignant effusions are tested for
their sensitivity to cisplatin and docetaxel using ATP-TCA assay.
Results: ERCC1 expression level is negatively correlated with the sensitivity to cisplatin in NSCLC
patients (P = 0.001). In NSCLC and gastric group, BRCA1 expression level is negatively correlated
with the sensitivity to cisplatin (NSCLC: P = 0.014; gastric: P = 0.002) while positively correlated
with sensitivity to docetaxel (NSCLC: P = 0.008; gastric: P = 0.032). A significant interaction is
found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P = 0.010, n =
45).
Conclusion: Our results demonstrate that ERCC1 and BRCA1 mRNA expression levels are
correlated with in vitro chemosensitivity to cisplatin and/or docetaxel in malignant effusions of
NSCLC and gastric cancer patients. And combination of ERCC1 and BRCA1 may have a better role
on predicting the sensitivity to cisplatin than the single one is considered.
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Background
The lack of understanding and accounting for inter-
patient variability in drug efficacy is one of the handicaps
in the field of chemotherapy, which inevitably leads to the
unpredictable disease responses and patient toxicities.
New advanced technology, such as phamacogenomics,
offers us a more efficient tool to explore the candidate
genes that influence drug activity and toxicity. Such stud-
ies make it possible to perform tailor chemotherapy based
on the specific genetic profile of individual patients [1,2].
Moreover, establishing any potent biomarkers for chemo-
therapy resistance will allow for the adoption of a better
chemotherapeutic regimen, which will maximize effica-
cies and minimize toxicities of chemotherapy.
Genetic alterations are one of the major reasons for
chemo-resistant in metastases[3]. Given the complicated
biological mechanisms evolved in the disease progress
and the heterogeneity between primary tumor and meta-
static tumor[3,4], certain biomarkers, which have been
proved to be effective to specific drug sensitivity in pri-
mary tumor-based studies, may not always serve the same
way in metastases. For example, the higher expression of
Xeroderma Pigmentosum A in metastatic effusion is asso-
ciated with better response to chemotherapy in ovarian
cancer patients, paradoxically to the results in primary
tumor [5] However, low expression of thymidylate syn-
thase (TS) in metastases is associated with response to 5-
FU based therapy in advanced gastric disease [6,7], paral-
leling to those findings based on primary tumor tissues
[8]. In order to develop better therapies and improve
patients' outcome, one of the urgent work is to explore
more effective biomarkers for chemosensitivity in metas-
tases, which is the leading cause of cancer-related death in
the world [4].
The excision repair cross-complementing group 1 gene
(ERCC1), an essential member of the nucleotide excision
repair (NER) pathway which accounts for the majority of
platinum-DNA adduct repair, has been established as a
useful molecular marker for NER activity. Early studies
have shown that higher ERCC1 mRNA levels are associ-
ated with a more active DNA repair process in various tis-
sues [9]. Interestingly, ERCC1 expression is also
associated with cellular and clinical resistance to platinum
compounds and to platinum-based chemotherapy,
including lung and gastric malignancies [10-12]. Breast
cancer susceptibility gene 1 (BRCA1), an essential compo-
nent in multiple DNA damage repair pathways and path-
ways involved in cellular responses to microtubule
damage, is considered to be a differential modulator of
survival with cisplatin and taxanes [13-16]. Preclinical
and clinical studies have reported that BRCA1 level is
associated with cisplatin [14,17] and taxanes chemosensi-
tivity [18,19]. Although above studies suggested that both
ERCC1 and BRCA1 may serve as effective biomarkers for
chemosensitivity in cancer patients with primary tumor,
the information on these biomarkers is still limited in
metastases.
Current study is therefore designed to explore the possi-
bility of using ERCC1 and BRCA1 as two effective drug
sensitivity biomarkers in malignant effusion specimens,
in which all malignant cells are metastatic. We measured
mRNA level of ERCC1 and BRCA1 in tumor cells isolated
from malignant effusions and correlated them with cispl-
atin and/or docetaxel chemosensitivity in vitro. And we
also verified the effect of combination ERCC1 and BRCA1
on the prediction of chemosensitivity to cisplatin.
Methods
Patients
All specimens and relevant clinical data were obtained
from the department of oncology, respiratory and diges-
tion, Drum Tower Hospital, Nanjing, China, during the
period from June 2005 to December 2006. Malignant
effusions were obtained from forty-six patients who have
been histological or cytological diagnosis as stage IV
malignant disease. Nine gastric cancer patients have
received chemotherapy based on a semi-monthly regimen
of 5-FU (5-fluorouracil), leucovorin and oxaliplatin
before the appearance of effusions. Clinical characteristics
of the patients are summarized in Table 1. In all speci-
mens included in this study, cancer cells comprised at
least 50% of the entire cells population based on cytology
smears performed by the experienced pathologist.
Informed consent was obtained from all patients and the
protocols for this study were approved by the Human
Research Protective Committee of our hospital.
Sample collection and processing
All patients received catheter placement using an indwell-
ing 16 G single lumen central venous catheter (CVC)
(Arrow™ 16 G CVC set Catheter, Arrow, USA). Effusions
were collected in sterile drainage bag with heparin
(10,000 U/L effusions) added previously, submitted to
our laboratory within minutes and were processed imme-
diately. Samples were centrifuged at 1000 g for 10 minute
to collect cells. After Ficoll-Hypaque (specific gravity
1.077, Pharmacia) density centrifugation, the interface
layer was collected. The quality and viability of the cell
suspension were assessed by trypan blue dye exclusion
and cytological examination. Cells were counted, washed
and centrifuged for later ATP-TCA assay and RNA extrac-
tion.
RNA isolation and cDNA synthesis
Total cell RNA was extracted using Trizol Reagent (Invitro-
gen, CA, USA) following the manufacture's protocol.BMC Cancer 2008, 8:97 http://www.biomedcentral.com/1471-2407/8/97
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cDNA was generated using Exscript™ RT reagent Kit
(TaKaRa) according to manufacture's protocol.
Real time PCR quantification
Quantitation of the genes of interest and an internal refer-
ence gene (β-actin) was done using a fluorescence based
real-time detection method (Mx3000P Real Time PCR
System, Stratagene). Briefly, 2 µl of cDNA were used for
each RT reaction. The 20 µl PCR reaction mixture con-
tained 1× primers & probe mixture (Applied Biosystems,
Foster city, CA. Assay IDs: Hs00157415_m1 (ERCC1);
Hs00173233_m1 (BRCA1); Hs99999903_m1(β-actin)),
1× Absolute QPCR Mix (ABgene, Surrey, UK). The PCR
conditions were 50°C for 2 min, 95°C for 15 min, fol-
lowed by 45 cycles at 95°C for 15 s and 60°C for 1 min.
Each sample was assayed in triplicate with commercial
RNA as positive and RNase-free water as negative control.
Relative gene expression quantifications were calculated
according to the comparative Ct method using β-actin as
an endogenous control and commercial RNA (Clontech)
control as calibrators on each plate. Final results were
determined by the formula 2-∆∆Ct[17] and were analyzed
with the Stratagene analysis software.
Evaluation of sensitivity to anti-cancer drugs using ATP-
TCA
The chemosensitivity test was performed with primary
tumor cells from malignant effusions as described before
[20]. Briefly, assays were performed in 96-well polypro-
pylene microplates(Corning-Costar 3790, NY, USA). Test
drug concentrations were administrated in triplicate in six
different concentrations: 0.234, 0.475, 0.95, 1.9, 3.8, and
7.6 µg·ml-1 cisplatin (QiLu Pharma. Co., China) or 0.288,
0.575, 1.15, 2.3, 4.6, and 9.2 µg·ml-1 docetaxel (Hengrui
Pharma. Co., China). Subsequently, 100 µl of single cell
suspension (2×105 /ml) in serum-free medium (CAM;
DCS, Innovative Diagnostic Systeme, Hamberg, Ger-
many) were added to each well. Two rows of the plate
were reserved for controls, negative control (no drug,
MO) and positive control (maximum ATP inhibitor, MI).
After 6 days incubation at 37°C and 95% humidity in 5%
CO2 atmosphere, intracellular ATP was extracted using the
CellTiter-GIo Luminescent Kit (Promega, USA) according
to the manufacturer's instructions and measured by
microplate luminometer (Berthod Diagnostic system,
Germany). A sensitivity index ranging from 0 to 600 for
each drug was calculated by summing up the percentage
of cell viability at the six drug concentrations tested [21].
Thus, a sensitivity index of 0 indicates maximal drug sen-
sitivity, whereas a sensitivity index of 600 reflects minimal
drug sensitivity.
Statistics
Spearman correlation coefficient was adopted to analysis
the correlation between gene expression levels and drug
sensitivity. ANOVA was used to evaluate the interaction of
ERCC1 and BRCA1 on sensitivity to cisplatin. All values
were based on two tailed statistical analysis. P value < 0.05
was considered statistically significant. Statistical analyses
were done using SPSS 13.0 (SPSS Inc, Chicago, Illinois,
USA).
ATP-TCA
To determine the sensitivity to these drugs, primary tumor
cells were isolated from malignant effusions and their
chemosensitivity to cisplatin and docetaxel were assessed
using the ATP-TCA assay. The serum free medium and
polypropylene 96-well "U" microplates can enrich tumor
cells up to 80–90%, reducing potential interference of
non-tumor cells [20,22]. And we have also proved the
raise of tumor cells number by the end of 6-days culture
in our preliminary test. Due to the strict sterile operation,
sample processing and only the specimens containing at
least 50% cancer cells enrolling, assays were successfully
performed on all samples. Table 2 summarized the result
of ATP-TCA on different subsets.
ERCC1 expression and cisplatin chemosensitivity
Except one specimen from NSCLC patients, ERCC1 were
amplified in all other samples. The median ERCC1 mRNA
expression was 0.057 (range: 0.005–0.831, n = 45). Figure
1 shows a significant correlation between ERCC1 mRNA
Table 1: Demographic and clinical parameters of patients (n = 
46)
Patients
Characteristics No. %
Age, years
Median 63
Range 38–87
Sex
Female 21 46
Male 25 54
Stage IV 46 100
ECOG performance status
0–2 46 100
Primary Tumor
NSCLC 20 43
Gastric 21 46
Gynecological 5 11
Sample type
Pleural effusions 21 46
Peritoneal effusions 25 54
Pre-Chemotherapy
Yes 9 20
No 37 80
Abbreviation: ECOG, Eastern Cooperative Oncology Group.BMC Cancer 2008, 8:97 http://www.biomedcentral.com/1471-2407/8/97
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expression and sensitivity to cisplatin in malignant pleu-
ral effusions of NSCLC patients (P = 0.001, r = 0.685).
Patients with lower ERCC1 mRNA expression levels had a
higher sensitivity to cisplatin compared with those with
higher expression levels. However in gastric group, we did
not find a significant association between ERCC1 mRNA
expression and cisplatin chemosensitivity (P = 0.482, r =
0.162). Considering ERCC1 expression is up-regulated in
response to cisplatin exposure [23] and 9 patients have
been treated with oxaliplatin before, we deduced that pre-
vious exposure to platinum might induce alterations on
ERCC1 gene expression, which could be different accord-
ing to individual patient. When nine pre-treated patients
were excluded from this group, a significantly correlation
between the level of ERCC1 and chemosensitivity to cispl-
atin was found in untreated gastric patients (P = 0.014, r =
0.685; Figure 2).
BRCA1 expression and cisplatin chemosensitivity
We next analyzed the correlation between BRCA1 mRNA
expression and cisplatin chemosensitivity in malignant
effusions. BRCA1 mRNA expression was detectable by
quantitative RT-PCR in all samples. The median level was
2.209×10-3  (range, 0.019–188.645×10-3, n = 46). As
shown in Figure 3 and 4, BRCA1 mRNA expression levels
were inversely correlated with sensitivity to cisplatin in
malignant pleural effusions of NSCLC patients (P = 0.014,
r = 0.541; Figure 3) and in ascites of gastric patients (P =
0.002, r = 0.624; Figure 4).
BRCA1 expression and docetaxel chemosensitivity
On the opposite site of its prediction value for cisplatin
sensitivity, BRCA1 mRNA expression levels in malignant
effusions were positively correlated with sensitivity to
docetaxel, in which patients with higher BRCA1 mRNA
expression levels had a higher sensitivity to docetaxel
compared with those with lower expression levels
(NSCLC: P = 0.008, r = -0.573, Figure 5; gastric: P = 0.032,
r = -0.468; Figure 6). We further noticed that the correla-
tion between BRCA1 mRNA expression and docetaxel
ERCC1 mRNA expression levels were significant association  with sensitivity to cisplatin in 12 untreated gastric cancer  patients (P = 0.014, r = 0.685) Figure 2
ERCC1 mRNA expression levels were significant 
association with sensitivity to cisplatin in 12 
untreated gastric cancer patients (P = 0.014, r = 
0.685).
Table 2: In vitro chemosensitivity assay results
Cytotoxic drug Total NSCLC Gastric Gynecological
Sensitivity Index of Median (range), No. patients
Docetaxel 455 (206–600), 46 422 (206–566), 20 513 (382–600), 21 364 (206–438), 5
Cisplatin 442 (184–600), 46 445 (184–558), 20 455 (273–600), 21 387 (301–464), 5
A sensitivity index of 0 indicates maximal drug sensitivity,  whereas a sensitivity index of 600 reflects minimal drug sen- sitivity Figure 1
A sensitivity index of 0 indicates maximal drug sensi-
tivity, whereas a sensitivity index of 600 reflects mini-
mal drug sensitivity. Relative ERCC1 mRNA expression 
(logarithmically transformed) was positively correlated with 
resistance to cisplatin in 19 NSCLC patients (P = 0.001, r = 
0.685).BMC Cancer 2008, 8:97 http://www.biomedcentral.com/1471-2407/8/97
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chemosensitivity in gastric group was due to the two
extreme points, and that a higher number of samples
would be necessary to confirm it.
Combination of two genes and sensitivity to cisplatin
As both ERCC1 and BRCA1 were correlated with cisplatin
chemosensitivity, we further investigated the effect of
combination of them on the sensitivity to cisplatin. A sig-
nificant interaction was found between BRCA1 and
ERCC1 gene expression on the sensitivity to cisplatin in
total group (P = 0.010, n = 45) and gastric group (P =
0.027, n = 21). When both ERCC1 and BRCA1 were lowly
expressed, the sensitivity to cisplatin was improved and
which was higher than the sum of the degrees when only
single marker was lowly expressed. This could be
explained as combination of low expression levels of
Relationship between BRCA1 mRNA expression and sensi- tivity to docetaxel in 21 gastric cancer patients (P = 0.032, r  = -0.468) Figure 6
Relationship between BRCA1 mRNA expression and 
sensitivity to docetaxel in 21 gastric cancer patients 
(P = 0.032, r = -0.468).
Relationship between BRCA1 and sensitivity to cisplatin in 21  gastric cancer patients (P = 0.002, r = 0.624) Figure 4
Relationship between BRCA1 and sensitivity to cispl-
atin in 21 gastric cancer patients (P = 0.002, r = 
0.624).
Relative BRCA1 mRNA expression levels (logarithmically  transformed) were positively correlated with resistance to  cisplatin in 20 NSCLC patients (P = 0.014, r = 0.541) Figure 3
Relative BRCA1 mRNA expression levels (logarith-
mically transformed) were positively correlated with 
resistance to cisplatin in 20 NSCLC patients (P = 
0.014, r = 0.541).
BRCA1 mRNA expression levels (logarithmically trans- formed) were negatively correlated with resistance to  docetaxel in 20 NSCLC patients (P = 0.008, r = -0.573) Figure 5
BRCA1 mRNA expression levels (logarithmically 
transformed) were negatively correlated with resist-
ance to docetaxel in 20 NSCLC patients (P = 0.008, r 
= -0.573).BMC Cancer 2008, 8:97 http://www.biomedcentral.com/1471-2407/8/97
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ERCC1 and BRCA1 correlated with more sensitivity to cis-
platin than single marker being considered. Similar trend
was also found in NSCLC group without statistical signif-
icance (P = 0.12, n = 19).
Discussion
The primary purpose of this study was to determine the
correlation between ERCC1 and BRCA1 mRNA expres-
sion and sensitivity to cisplatin and/or docetaxel in special
metastases, malignant effusions. We use body cavity as a
specific metastatic site in current study based on following
reasons. Firstly, tumor cells in malignant effusions have
distinct characteristics such as loss of interaction with stro-
mal and endothelial cells, reduced availability of oxygen
and nutrients [24]. Secondly, it is easy, non-invasive and
repeatable to obtain effusion samples from inoperable
lung or gastric cancer patients with malignant effusions
[25]. Finally, malignant effusion is a complication of var-
ious advanced malignant disease. Approximately half of
all patients with metastatic cancer develop a malignant
effusion at the course of disease [26].
ATP-TCA, a well established in vitro assay, has been dem-
onstrated as a valuable tool for the evaluation of chemo-
sensitivity in solid tumors, as well as been shown to allow
a prediction of clinical results [21,27]. In the present
study, ATP-TCA was performed to evaluate the single
agent chemosensitivity in a consecutive series of 46 malig-
nant effusions. By using the in vitro assay, we excluded the
interference from other systematic therapy such as combi-
nation of other drugs and potential prognostic effects in
vivo, thus making the assessment between particular gene
expression and a given drug more precise. However,
chemosensitivity results from an in vitro study can not be
directly translated into clinical practice because the chem-
oresponse does not depend on intrinsic chemosensitivity
alone. Our future study will focus on the confirmation of
the relationship between these two genes expression in
malignant effusions and patients' clinical response in clin-
ical trial.
We observed a clear correlation between ERCC1 and
BRCA1 mRNA expression level and chemosensitivity to
cisplatin, one of the most widely used agent in both
NSCLC and gastric cancer. Both ERCC1 and BRCA1 were
negatively correlated with cisplatin sensitivity in pleural
effusions of NSCLC patient. In addition, BRCA1 mRNA
expression was negatively correlated with cisplatin sensi-
tivity in peritoneal effusions of gastric cancer patients,
while ERCC1 was correlated with cisplatin sensitivity only
in specimens of untreated gastric patients. Unlike ERCC1,
BRCA1 is involved in both homologous recombination
and nonhomologous end joining of double-stranded
DNA breaks and also in NER of DNA adducts [15,16]. It is
reasonable to speculate that the different mechanisms of
these two genes on DNA repair might be a possible expla-
nation for this disparity.
In comparison to the evidence linking ERCC1 to cisplatin
sensitivity, the link between BRCA1 and response to tax-
ane remains to be documented. We demonstrated a posi-
tively correlation between BRCA1 mRNA expression and
docetaxel sensitivity in malignant effusions in both
NSCLC and gastric patients. Our study showed that
patients with higher BRCA1 level in malignant effusions
are more sensitive to docetaxel than those with lower
level. This finding is in line with the previous reports
[18,19]. Knockdown of BRCA1 gene induce a 50-fold
increase in resistance to paclitaxel agents [18]. A recently
study show that absence of BRCA1 expression is a predic-
tor of shorter TTP (time to progression) in advanced
breast cancer patients treated with taxane-based therapy
[19]. Collectively, our findings supported the hypothesis
that BRCA1 and ERCC1 mRNA expression levels were cor-
related with sensitivity to docetaxel and/or cisplatin in
metastatic effusions, which is in consistent with previous
findings based on primary tumor.
Our second aim was to study whether the combination of
ERCC1 and BRCA1 could do better on predicting the
chemosensitivity to cisplatin. We observed the significant
interaction of BRCA1 and ERCC1 mRNA expression levels
on sensitivity to cisplatin in total and gastric cancer
patients. However, we did not obtain the same conclusion
in lung cancer patients. This might due to the small sam-
ple size and over-dispersion data, which would restrict the
statistical power to identify interaction effect in that panel.
According to our results, the combination of two biomar-
kers, ERCC1 and BRCA1, may play a better role in predict-
ing the cisplatin chemosensitivity than the single one
being considered.
Conclusion
In summary, our data demonstrated for the first time that
ERCC1 and BRCA1 mRNA expression levels were corre-
lated with cisplatin and/or docetaxel in the ex vivo study of
malignant effusions. Combination of ERCC1 and BRCA1
mRNA expression may have an interaction prediction on
the sensitivity to cisplatin.
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